AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19189246
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg), administered as vaginal suppositories daily for 7 nights
Trial: 11991625
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g lactulose meal
Trial: 11991625
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g sucrose meal followed by colonic infusion of 40 g lactulose
Trial: 9704778
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid and vitamin B6 supplementation with aspirin
Trial: 8556974
Drug: Mazindol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (2 mg QD)
Trial: 31714583
Drug: Glucagon (300/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (300/150 μg)
Trial: 29596222
Drug: Micafungin (MCA)
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin (MCA) 10 mg/kg/d for ≥21 days
Trial: 29596222
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B Deoxycholate (AmB-D) 1 mg/kg/d for ≥21 days
Trial: 28723799
Drug: TACE with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE with GSPs plus lobaplatin chemotherapy
Trial: 25028065
Drug: Encenicline (alpha-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encenicline (alpha-7 nicotine agonist)
Trial: 23319176
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of HZ vaccine (0.65 mL)
Trial: 23319176
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HZ vaccine at 0 and 1 month
Trial: 23319176
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HZ vaccine at 0 and 3 months
Trial: 23319176
Drug: Two-dose vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose vaccination (both schedules)
Trial: 18419402
Drug: HZ vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ vaccine
Trial: 22018642
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg for 6 months
Trial: 15571954
Drug: Intraventricular chemotherapy
RxNorm normalized name: cerliponase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricular chemotherapy (IT)
Trial: 15571954
Drug: Non-intrathecal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intrathecal treatment (non-IT)
Trial: 8106654
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 to 40 mg)
Trial: 8106654
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 to 60 mg)
Trial: 2446057
Drug: Ketanserin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20-40 mg b.i.d.)
Trial: 2446057
Drug: Methyldopa (250-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (250-500 mg b.i.d.)
Trial: 18520294
Drug: Sorafenib (monotherapy)
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib (monotherapy)
Trial: 18520294
Drug: Sorafenib (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (in combination with chemotherapy)
Trial: 18520294
Drug: Sorafenib (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (in combination with epidermal growth factor receptor inhibitors)
Trial: 18520294
Drug: Bevacizumab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (in combination with cytotoxic chemotherapy)
Trial: 15893182
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg and fenofibrate 200 mg
Trial: 16160590
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg
Trial: 12887139
Drug: Phentermine 37.5
RxNorm normalized name: PHENTERMINE 37.5MG TAB,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 37.5 mg
Trial: 26773325
Drug: lexaptepid pegol
RxNorm normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lexaptepid pegol (1.2 mg·kg(‐1) i.v.)
Trial: 26773325
Drug: lexaptepid pegol
RxNorm normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lexaptepid pegol (doses from 0.3 to 4.8 mg·kg(‐1))
Trial: 26773325
Drug: lexaptepid pegol
RxNorm normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lexaptepid pegol (≥2.4 mg·kg(‐1))
Trial: 26773325
Drug: lexaptepid pegol
RxNorm normalized name: Lexaptepid pegol
DrugBank: Lexaptepid pegol (DB12578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lexaptepid pegol (s.c. administration)
Trial: 21997675
Drug: Ingested water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingested water (300 ml labeled with D₂O; osmolality <20 mOsm kg(‐1))
Trial: 15462687
Drug: NSAIDs (ibuprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ibuprofen, diclofenac, nabumetone, or naproxen, combined, N = 7046)
Trial: 15884512
Drug: Subconjunctival MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival MMC (0.2 mg/ml for 3 minutes)
Trial: 15884512
Drug: Intrascleral MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrascleral MMC (0.2 mg/ml for 3 minutes)
Trial: 9598903
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate (10 mg/m2 body surface area/wk)
Trial: 9598903
Drug: D-penicillamine, hydroxychloroquine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine, hydroxychloroquine, auranofin, very low dose methotrexate
Trial: 8159444
Drug: Treatment: full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment: full occlusal splint worn 24 h/day
Trial: 23681967
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human ACE2 (rhACE2) 100-1200 μg/kg single dose
Trial: 23681967
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human ACE2 (rhACE2) 400 μg/kg repeated dosing for 3 or 6 days
Trial: 19685109
Drug: Priming with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming with vecuronium (0.02 mg.kg(‐1))
Trial: 19685109
Drug: Priming with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming with rocuronium (0.06 mg.kg(‐1))
Trial: 15271118
Drug: Nutrition supplements
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition supplements provided between breakfast and lunch for 21 consecutive days
Trial: 9685273
Drug: Intensive cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cognitive behaviour therapy
Trial: 2546659
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg b.i.d., orally)
Trial: 31300907
Drug: Laparoscopic pancreaticoduodenectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic pancreaticoduodenectomy (L-PD)
Trial: 23659666
Drug: Erythropoietin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (1000 IU/kg for three daily doses)
Trial: 23659666
Drug: Phenobarbital (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (40 mg/kg single dose)
Trial: 23659666
Drug: Control (supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (supportive treatment)
Trial: 21157296
Drug: K103N viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K103N viral load at least 2000 copies/ml
Trial: 15069730
Drug: Hemoperfusion adsorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoperfusion adsorption therapy
Trial: 3884114
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange therapy
Trial: 15069730
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange plus hemoperfusion adsorption therapy
Trial: 11834182
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Cupressus arizonica
Trial: 8290193
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac (60 mg)
Trial: 7618770
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (800 mg)
Trial: 9492131
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (ketorolac and ibuprofen)
Trial: 2577273
Drug: Maintenance drug
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance drug treatment
Trial: 2577273
Drug: Drug withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug withdrawal
Trial: 31707181
Drug: Modified gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified gemcitabine and oxaliplatin (mGemOx) - gemcitabine 900 mg/m2, oxaliplatin 80 mg/m2, maximum 6 cycles
Trial: 31707181
Drug: Gemcitabine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine + cisplatin (CisGem) - gemcitabine 1000 mg/m2, cisplatin 25 mg/m2, maximum 8 cycles
Trial: 28893900
Drug: Labetalol (200‐1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200‐1800 mg/d)
Trial: 28893900
Drug: Nifedipine (20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20‐80 mg/d)
Trial: 19689824
Drug: Kneipp hydrotherapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 0.001 mg in 1 mL / SODIUM BICARBONATE 0.05 mg in 1 mL TOPICAL LOTION [ProloGel Neurotherapy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kneipp hydrotherapy (daily, with alternate cold and warm thigh affusions)
Trial: 19689824
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physiotherapy and hydrotherapy (joint-specific physiotherapy three times a week and daily alternate cold and warm thigh affusions)
Trial: 24249722
Drug: ACEI-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI-based therapy
Trial: 10602973
Drug: iopromide 240
RxNorm normalized name: IOPROMIDE 240mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide 240 mgI/ml
Trial: 7731768
Drug: iohexol 240
RxNorm normalized name: iohexol 240 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 240 mgI/ml
Trial: 8529760
Drug: Insulin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.3 IU/Kg BW at 10-11 p.m.)
Trial: 31821361
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg/day)
Trial: 8529760
Drug: Acarbose (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (3 x 100 mg daily)
Trial: 29693715
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days)
Trial: 27574886
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin combined with insulin (LMWH+insulin)
Trial: 19406493
Drug: Enoxaparin and
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin and unfractionated heparin (no specific dosage or duration mentioned)
Trial: 20375405
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) supplementation
Trial: 9068393
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg alteplase
Trial: 4009330
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration with solution A and solution B
Trial: 29280064
Drug: Macitentan in
RxNorm normalized name: Product containing macitentan in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan in combination with background therapy (PDE‐5i)
Trial: 29280064
Drug: Background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background therapy only (placebo arm)
Trial: 26194532
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist analogue administered at a dose interval of 3 days and/or a monthly dose of GnRHa during chemotherapy
Trial: 26194532
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist analogue
Trial: 25450320
Drug: Protoconized anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protoconized anemia therapy with adjusted doses of erythropoietin, iron, and vitamin C based on Hb and ferritin levels.
Trial: 25450320
Drug: Non‐intervention group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐intervention group with doses of erythropoietin and iron determined by the attending physician.
Trial: 22435409
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil group (n = 24) using blended essential oils (lavender, clary sage, marjoram) in a 3% concentration cream, massaged daily on lower abdomen.
Trial: 18344428
Drug: Pilocarpine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine, 5 mg orally every 8 hours for 1 week after 131I therapy
Trial: 10556111
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microgram twice daily)
Trial: 10556111
Drug: Fluticasone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100 microgram twice daily)
Trial: 8739023
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg Y-27152
Trial: 8739023
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg Y-27152
Trial: 8739023
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Y-27152
Trial: 8739023
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg Y-27152 (fasting)
Trial: 8739023
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg Y-27152 (after food)
Trial: 8739023
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg Y-27152
Trial: 8739023
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Y-27152 (multiple doses)
Trial: 8739023
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg Y-27152 (multiple doses)
Trial: 8739023
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg Y-27152 (multiple doses)
Trial: 26746580
Drug: Therapy-as-usual control
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy-as-usual control group (no writing intervention)
Trial: 24852722
Drug: BCG vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccination at school age (first dose)
Trial: 20609482
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI, escitalopram)
Trial: 20609482
Drug: Tricyclic antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressant (TCA, nortriptyline)
Trial: 17921366
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (30 g fat/m(2), 35% fat)
Trial: 16120118
Drug: Fluconazole capsules
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole capsules (Zolax 50 mg once a day)
Trial: 16120118
Drug: Hexetidine mouthrinses
RxNorm normalized name: Hexetidine
DrugBank: Hexetidine (DB08958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexetidine mouthrinses (Heksoral 0.1%, twice daily)
Trial: 16120118
Drug: Fluconazole capsules
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole capsules and hexetidine mouthrinses for 14 days
Trial: 11934186
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment (debridement and short-term usage of antimicrobial agents)
Trial: 8695556
Drug: Peribulbar injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar injections of 5 ml of anaesthetic (study group 1)
Trial: 8695556
Drug: Peribulbar injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar injections of local anaesthetic (study group 2)
Trial: 28467859
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg)
Trial: 31145202
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) alone (0.625 mg/d)
Trial: 31145202
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + medroxyprogesterone acetate (MPA) (0.625 mg of CEE + 2.5 mg of MPA)
Trial: 20642246
Drug: Oxycodone HCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone HCI IR 10 or 15 mg
Trial: 17643772
Drug: 3 intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intradermal doses of 0.1 mL PCECV (Rabipur)
Trial: 17643772
Drug: 2 simulated
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 simulated post‐exposure booster doses 1 year after primary vaccination
Trial: 16224180
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy with biweekly administration of 1,000 mg/m² gemcitabine
Trial: 2643772
Drug: High-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subcutaneous heparin (12,500 units every 12 hours)
Trial: 2643772
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous heparin (5000 units every 12 hours)
Trial: 2643772
Drug: High-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subcutaneous heparin
Trial: 1104060
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous heparin
Trial: 7409300
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg o.d.)
Trial: 7409300
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg t.i.d.)
Trial: 29962180
Drug: Rosuvastatin in
RxNorm normalized name: Product containing rosuvastatin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin in combination with nimodipine
Trial: 29687966
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation plus laser therapy and exercise (SM-LT-CE)
Trial: 29687966
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy and exercise (LT-CE)
Trial: 22824834
Drug: 12 mcg/h
RxNorm normalized name: fentanyl 12 MCG/HR 3 Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mcg/h fentanyl patch
Trial: 22824834
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control patch
Trial: 17517060
Drug: Methodological and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methodological and statistical features of RCTs in implant therapy
Trial: 28117496
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel
Trial: 10527977
Drug: Norplant implants
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norplant implants (NOR)
Trial: 7588177
Drug: Antidepressants (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (full dosage)
Trial: 7588177
Drug: Long term
RxNorm normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term antidepressants (in bipolar disorders)